Kiniksa Pharmaceuticals, Ltd. Q2 2026 Earnings Recap

KNSA Q2 2026 July 30, 2026

Get alerts when KNSA reports next quarter

Kiniksa shares surged 27.4% following significant upside in ARCALYST commercial performance and raised full-year revenue guidance, signaling strong execution and expanding market penetration.

Earnings Per Share Beat

$0.30 vs $0.30 est.

+0.2% surprise

Revenue Beat

243600000 vs 226488400 est.

+7.6% surprise

Market Reaction

1-Day -4.94%

5-Day -2.16%

See KNSA alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q2 net revenue reached $243.6 million, up over $29 million sequentially and $85 million versus Q2 2025, marking the largest quarterly increase since launch.
Full-year 2026 revenue guidance was raised from $945 million to a range of $980 million to $995 million.
ARCALYST’s prescriber base expanded to over 5,000, with approximately 450 new prescribers added in Q2 and 29% now prescribing for multiple patients.
Penetration into the multiple recurrence patient population increased to ~21% from ~18% at the end of 2025.
The company advanced KPL-387 into Phase III trials, targeting a commercial launch in 2028–2029.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit KNSA on AllInvestView.

Previous Q3 2025